Research programme: cancer metabolism modulators - Dynamix

Drug Profile

Research programme: cancer metabolism modulators - Dynamix

Alternative Names: DNX-03000; DNX-03024; DNX-06000; DNX-3000; DNX-6000; PKM2 activators - Dynamix

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dynamix Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Glycolysis modulators; Pyruvate kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Israel (PO)
  • 15 Jun 2011 Research programme: cancer metabolism enzyme modulators - Dynamix is available for licensing as of 15 Jun 2011. http://www.dynxp.com
  • 05 Apr 2011 Preclinical trials in Solid tumours in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top